Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.40 |
| ▸ | BAD | Q92934 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168073 | 0.83 | PTGDR2 (0.52) | PTGDR2PPARGMCL1BADPPARA | |
| SCHEMBL4416672 | 0.82 | PTGDR2 (0.47) | PTGDR2PPARGMCL1BADPPARA | |
| SCHEMBL12678715 | 0.82 | PTGDR2 (0.45) | PTGDR2PPARGMCL1BADPPARA | |
| SCHEMBL3169645 | 0.79 | PTGDR2 (0.55) | PTGDR2MCL1 | |
| SCHEMBL3168468 | 0.78 | PTGDR2 (0.57) | PTGDR2PPARGMCL1PPARA | |
| SCHEMBL4414924 | 0.78 | PTGDR2 (0.52) | PTGDR2MCL1BAD | |
| SCHEMBL12678737 | 0.77 | PTGDR2 (0.50) | PTGDR2PPARGPPARA | |
| SCHEMBL3159505 | 0.71 | PTGDR2 (0.45) | PTGDR2 | |
| SCHEMBL3159691 | 0.70 | PTGDR2 (0.90) | PTGDR2MCL1 | |
| SCHEMBL3176752 | 0.69 | PTGDR2 (0.70) | PTGDR2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PPARG 1069/4885MCL1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.